
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Department of Pathology, State University of New York at Stony Brook, Stony Brook, NY
Requests for reprints: Ute M. Moll, Department of Pathology, State University of New York at Stony Brook, Stony Brook, NY 11794-8691. Phone: (631) 444-2459; Fax: (631) 444-3424. E-mail: umoll{at}notes.cc.sunysb.edu
Abstract
Activation of the p53 protein protects the organism against the propagation of cells that carry damaged DNA with potentially oncogenic mutations. MDM2, a p53-specific E3 ubiquitin ligase, is the principal cellular antagonist of p53, acting to limit the p53 growth-suppressive function in unstressed cells. In unstressed cells, MDM2 constantly monoubiquitinates p53 and thus is the critical step in mediating its degradation by nuclear and cytoplasmic proteasomes. The interaction between p53 and MDM2 is conformation-based and is tightly regulated on multiple levels. Disruption of the p53-MDM2 complex by multiple routes is the pivotal event for p53 activation, leading to p53 induction and its biological response. Because the p53-MDM2 interaction is structurally and biologically well understood, the design of small lipophilic molecules that disrupt or prevent it has become an important target for cancer therapy.
This article has been cited by other articles:
![]() |
B. Z. Carter, D. H. Mak, W. D. Schober, M. F. Dietrich, C. Pinilla, L. T. Vassilev, J. C. Reed, and M. Andreeff Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5 Blood, April 1, 2008; 111(7): 3742 - 3750. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Lukashchuk and K. H. Vousden Ubiquitination and Degradation of Mutant p53 Mol. Cell. Biol., December 1, 2007; 27(23): 8284 - 8295. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sandoval, M. Morales, R. Tapia, L. del Carmen Alarcon, M. Sordo, P. Ostrosky-Wegman, A. Ortega, and E. Lopez-Bayghen p53 Response to Arsenic Exposure in Epithelial Cells: Protein Kinase B/Akt Involvement Toxicol. Sci., September 1, 2007; 99(1): 126 - 140. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. O'Brien, V. Barnes, L. Zhao, R. A. McKnight, X. Yu, C. W. Callaway, L. Wang, J. C. Sun, M. J. Dahl, A. Wint, et al. Uteroplacental insufficiency decreases p53 serine-15 phosphorylation in term IUGR rat lungs Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R314 - R322. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Herrmann, L. O. Lerman, and A. Lerman Ubiquitin and Ubiquitin-Like Proteins in Protein Regulation Circ. Res., May 11, 2007; 100(9): 1276 - 1291. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kojima, M. Konopleva, I. J. Samudio, V. Ruvolo, and M. Andreeff Mitogen-Activated Protein Kinase Kinase Inhibition Enhances Nuclear Proapoptotic Function of p53 in Acute Myelogenous Leukemia Cells Cancer Res., April 1, 2007; 67(7): 3210 - 3219. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Malmlof, E. Roudier, J. Hogberg, and U. Stenius MEK-ERK-mediated Phosphorylation of Mdm2 at Ser-166 in Hepatocytes: Mdm2 IS ACTIVATED IN RESPONSE TO INHIBITED Akt SIGNALING J. Biol. Chem., January 26, 2007; 282(4): 2288 - 2296. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Alazzouzi, G. Suriano, A. Guerra, A. Plaja, E. Espin, M. Armengol, P. Alhopuro, S. Velho, Y. Shinomura, J. J. Gonzalez-Aguilera, et al. Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells J. Med. Genet., January 1, 2007; 44(1): 75 - 80. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Lopez-Knowles, S. Hernandez, M. Kogevinas, J. Lloreta, A. Amoros, A. Tardon, A. Carrato, S. Kishore, C. Serra, N. Malats, et al. The p53 Pathway and Outcome among Patients with T1G3 Bladder Tumors. Clin. Cancer Res., October 15, 2006; 12(20): 6029 - 6036. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Pereg, S. Lam, A. Teunisse, S. Biton, E. Meulmeester, L. Mittelman, G. Buscemi, K. Okamoto, Y. Taya, Y. Shiloh, et al. Differential Roles of ATM- and Chk2-Mediated Phosphorylations of Hdmx in Response to DNA Damage. Mol. Cell. Biol., September 1, 2006; 26(18): 6819 - 6831. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Baserga, M. A. Hale, X. Ke, Z. M. Wang, X. Yu, C. W. Callaway, R. A. McKnight, and R. H. Lane Uteroplacental insufficiency increases p53 phosphorylation without triggering the p53-MDM2 functional circuit response in the IUGR rat kidney Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2006; 291(2): R412 - R418. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kojima, M. Konopleva, T. McQueen, S. O'Brien, W. Plunkett, and M. Andreeff Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia Blood, August 1, 2006; 108(3): 993 - 1000. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Boersma, T. M. Howe, J. E. Goodman, H. G. Yfantis, D. H. Lee, S. J. Chanock, and S. Ambs Association of Breast Cancer Outcome With Status of p53 and MDM2 SNP309. J Natl Cancer Inst, July 5, 2006; 98(13): 911 - 919. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Valbuena, F. M. Vega, S. Blanco, and P. A. Lazo p53 Downregulates Its Activating Vaccinia-Related Kinase 1, Forming a New Autoregulatory Loop. Mol. Cell. Biol., July 1, 2006; 26(13): 4782 - 4793. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Harms and X. Chen p19ras Brings a New Twist to the Regulation of p73 by Mdm2 Sci. Signal., May 30, 2006; 2006(337): pe24 - pe24. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Novakovic, J. M. Stempak, K.-J. Sohn, and Y.-I. Kim Effects of folate deficiency on gene expression in the apoptosis and cancer pathways in colon cancer cells Carcinogenesis, May 1, 2006; 27(5): 916 - 924. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. White, K. E. Talbott, N. C. Arva, and J. Bargonetti Mouse Double Minute 2 Associates with Chromatin in the Presence of p53 and Is Released to Facilitate Activation of Transcription. Cancer Res., April 1, 2006; 66(7): 3463 - 3470. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tabakin-Fix, I. Azran, Y. Schavinky-Khrapunsky, O. Levy, and M. Aboud Functional inactivation of p53 by human T-cell leukemia virus type 1 Tax protein: mechanisms and clinical implications Carcinogenesis, April 1, 2006; 27(4): 673 - 681. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Gueven, O. J. Becherel, G. Birrell, P. Chen, G. DelSal, J. P. Carney, P. Grattan-Smith, and M. F. Lavin Defective p53 Response and Apoptosis Associated with an Ataxia-Telangiectasia-like Phenotype. Cancer Res., March 15, 2006; 66(6): 2907 - 2912. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Yang, M. Fraser, U. M. Moll, A. Basak, and B. K. Tsang Akt-Mediated Cisplatin Resistance in Ovarian Cancer: Modulation of p53 Action on Caspase-Dependent Mitochondrial Death Pathway. Cancer Res., March 15, 2006; 66(6): 3126 - 3136. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Giglio, F. Mancini, F. Gentiletti, G. Sparaco, L. Felicioni, F. Barassi, C. Martella, A. Prodosmo, S. Iacovelli, F. Buttitta, et al. Identification of an Aberrantly Spliced Form of HDMX in Human Tumors: A New Mechanism for HDM2 Stabilization Cancer Res., November 1, 2005; 65(21): 9687 - 9694. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kojima, M. Konopleva, I. J. Samudio, M. Shikami, M. Cabreira-Hansen, T. McQueen, V. Ruvolo, T. Tsao, Z. Zeng, L. T. Vassilev, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy Blood, November 1, 2005; 106(9): 3150 - 3159. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ma, J. Wagner, J. J. Rice, W. Hu, A. J. Levine, and G. A. Stolovitzky A plausible model for the digital response of p53 to DNA damage PNAS, October 4, 2005; 102(40): 14266 - 14271. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kosakowska-Cholody, W. M. Cholody, A. Monks, B. A. Woynarowska, and C. J. Michejda WMC-79, a potent agent against colon cancers, induces apoptosis through a p53-dependent pathway Mol. Cancer Ther., October 1, 2005; 4(10): 1617 - 1627. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mohapatra, B. Chu, X. Zhao, and W.J. Pledger Accumulation of p53 and Reductions in XIAP Abundance Promote the Apoptosis of Prostate Cancer Cells Cancer Res., September 1, 2005; 65(17): 7717 - 7723. [Abstract] [Full Text] [PDF] |
||||
![]() |
P Alhopuro, S K Ylisaukko-oja, W J Koskinen, P Bono, J Arola, H J Jarvinen, J-P Mecklin, T Atula, R Kontio, A A Makitie, et al. The MDM2 promoter polymorphism SNP309T->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck J. Med. Genet., September 1, 2005; 42(9): 694 - 698. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Krummel, C. J. Lee, F. Toledo, and G. M. Wahl The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation PNAS, July 19, 2005; 102(29): 10188 - 10193. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hengstermann, M. A. D'silva, P. Kuballa, K. Butz, F. Hoppe-Seyler, and M. Scheffner Growth Suppression Induced by Downregulation of E6-AP Expression in Human Papillomavirus-Positive Cancer Cell Lines Depends on p53 J. Virol., July 15, 2005; 79(14): 9296 - 9300. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Pereg, D. Shkedy, P. de Graaf, E. Meulmeester, M. Edelson-Averbukh, M. Salek, S. Biton, A. F. A. S. Teunisse, W. D. Lehmann, A. G. Jochemsen, et al. Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage PNAS, April 5, 2005; 102(14): 5056 - 5061. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Slack, Z. Chen, R. Tonelli, M. Pule, L. Hunt, A. Pession, and J. M. Shohet The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma PNAS, January 18, 2005; 102(3): 731 - 736. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-C. Wang, R.-K. Lin, Y.-H. Tan, J.-T. Chen, C.-Y. Chen, and Y.-C. Wang Wild-Type p53 Overexpression and Its Correlation With MDM2 and p14ARF Alterations: An Alternative Pathway to Non-Small-Cell Lung Cancer J. Clin. Oncol., January 1, 2005; 23(1): 154 - 164. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Feng, R. Tamaskovic, Z. Yang, D. P. Brazil, A. Merlo, D. Hess, and B. A. Hemmings Stabilization of Mdm2 via Decreased Ubiquitination Is Mediated by Protein Kinase B/Akt-dependent Phosphorylation J. Biol. Chem., August 20, 2004; 279(34): 35510 - 35517. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. Schonthal, C. R. Herzog, M. V. Swamy, and C. V. Rao Correspondence re: M. V. Swamy et al., Inhibition of COX-2 in Colon Cancer Cell Lines by Celecoxib Increases the Nuclear Localization of Active p53. Cancer Res 2003;63:5239-42. Cancer Res., April 15, 2004; 64(8): 2937 - 2938. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |